Literature DB >> 30740878

Rectal Surgery Evaluation Trial: protocol for a parallel cohort trial of outcomes using surgical techniques for total mesorectal excision with low anterior resection in high-risk rectal cancer patients.

P Rouanet1, S Gourgou2, I Gogenur3, D Jayne4, A Ulrich5, T Rautio6, G Spinoglio7, N Bouazza8, A Moussion8, M Gomez Ruiz9.   

Abstract

AIM: Total mesorectal excision (TME) is the standard of care for rectal cancer, which can be combined with low anterior resection (LAR) in patients with mid-to-low rectal cancer. The narrow pelvic space and difficulties in obtaining adequate exposure make surgery technically challenging. Four techniques are used to perform the surgery: open laparotomy, laparoscopy, robot-assisted surgery and transanal surgery. Comparative data for these techniques are required to provide clinical data on the surgical management of rectal cancers.
METHODS: The Rectal Surgery Evaluation Trial will be a prospective, observational, case-matched, four-cohort, multicentre trial designed to study TME with LAR using open laparotomy, laparoscopy, robot-assisted surgery or transanal surgery in high-surgical-risk patients with mid-to-low non-metastatic rectal cancer. All surgeries will be performed by surgeons experienced in at least one of the techniques. Oncological, morbidity and functional outcomes will be assessed in a composite primary outcome, with success defined as circumferential resection margin ≥ 1 mm, TME Grade III and minimal postoperative morbidity (absence of Clavien-Dindo Grade III-IV complications within 30 days after surgery). Secondary end-points will include the co-primary end-points over the long term (2 years), quality of surgery, quality of life, length of hospital stay, operative time and rate of unplanned conversions. DISCUSSION: This will be the first trial to study all four surgical techniques currently used for TME with LAR in a specific group of high-risk patients. The knowledge obtained will contribute towards helping physicians determine the advantages of each technique and which may be the most appropriate for their patients. Colorectal Disease
© 2019 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  laparoscopy; laparotomy; rectal cancer; robot-assisted surgery; transanal surgery

Mesh:

Year:  2019        PMID: 30740878     DOI: 10.1111/codi.14581

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

1.  Are oncological long-term outcomes equal after laproscopic completed and converted laparoscopic converted rectal resection for cancer?

Authors:  M Finochi; B Menahem; G Lebreton; J Lubrano; Y Eid; A Alves
Journal:  Tech Coloproctol       Date:  2020-08-28       Impact factor: 3.781

2.  Laparoscopic surgery facilitates administration of adjuvant chemotherapy in locally advanced colon cancer: propensity score analyses.

Authors:  Karin Atgm Wasmann; Charlotte El Klaver; Jarmila Dw van der Bilt; Susan van Dieren; Iris D Nagtegaal; Cornelis Ja Punt; Bert van Ramshorst; Albert M Wolthuis; Johannes Hw de Wilt; André D'Hoore; Hjalmar C van Santvoort; Pieter J Tanis
Journal:  Cancer Manag Res       Date:  2019-07-29       Impact factor: 3.989

3.  Combined robotic approach and enhanced recovery after surgery pathway for optimization of costs in patients undergoing proctectomy.

Authors:  P Rouanet; A Mermoud; M Jarlier; N Bouazza; A Laine; H Mathieu Daudé
Journal:  BJS Open       Date:  2020-04-30

4.  European expert consensus on a structured approach to training robotic-assisted low anterior resection using performance metrics.

Authors:  S Tou; M Gómez Ruiz; A G Gallagher; K E Matzel
Journal:  Colorectal Dis       Date:  2020-08-17       Impact factor: 3.917

Review 5.  Evolution of transanal total mesorectal excision according to the IDEAL framework.

Authors:  Sapho Xenia Roodbeen; Annalisa Lo Conte; Allison Hirst; Marta Penna; Willem A Bemelman; Pieter J Tanis; Roel Hompes
Journal:  BMJ Surg Interv Health Technol       Date:  2019-07-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.